Efficacy and safety of surufatinib in the treatment of patients with neuroendocrine tumor: a real-world study in Chinese population
Primary tumor site is a critical factor influencing the efficacy of surufatinib in NETs. Clinicians should consider this factor when determining treatment strategies.
Authors
- Jinqi You
- Yan Tang (ORCID: https://orcid.org/0000-0002-1377-422X)
- Jingjing Zhao (ORCID: https://orcid.org/0000-0002-5089-7608)
- Minxing Li
- Songzuo Xie (ORCID: https://orcid.org/0009-0000-3266-1864)
- Desheng Weng (ORCID: https://orcid.org/0009-0004-9677-8307)
- Yan Wang (ORCID: https://orcid.org/0000-0003-2563-255X)
- Yuanyuan Liu (ORCID: https://orcid.org/0000-0002-2097-5708)
- Xinyi Yang (ORCID: https://orcid.org/0000-0003-2638-5482)
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Third Affiliated Hospital of Sun Yat-sen University (CN)
Publication Details
- Journal
- BMC Cancer
- Published
- 2024-10-31
- DOI
- https://doi.org/10.1186/s12885-024-13089-6
- Citations
- 3
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.16
Funders
- Natural Science Foundation of Guangdong Province
- Basic and Applied Basic Research Foundation of Guangdong Province